NCT04672369View on ClinicalTrials.gov

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

PHASE1CompletedINTERVENTIONAL

Enrollment

42

Participants

Timeline

Start Date

June 6, 2021

Primary Completion Date

January 1, 2023

Study Completion Date

June 1, 2023

Conditions

Advanced Lung Cancer

Interventions

BIOLOGICAL

IBI939

IBI939 injection

BIOLOGICAL

Sintilimab

Sintilimab injection

Trial Locations (1)

Unknown

Jilin Province Cancer Hospital, Jilin

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY